» Articles » PMID: 36795481

Coordinated Activation of C-Src and FOXM1 Drives Tumor Cell Proliferation and Breast Cancer Progression

Abstract

Activation of the tyrosine kinase c-Src promotes breast cancer progression and poor outcomes, yet the underlying mechanisms are incompletely understood. Here, we have shown that deletion of c-Src in a genetically engineered model mimicking the luminal B molecular subtype of breast cancer abrogated the activity of forkhead box M1 (FOXM1), a master transcriptional regulator of the cell cycle. We determined that c-Src phosphorylated FOXM1 on 2 tyrosine residues to stimulate its nuclear localization and target gene expression. These included key regulators of G2/M cell-cycle progression as well as c-Src itself, forming a positive feedback loop that drove proliferation in genetically engineered and patient-derived models of luminal B-like breast cancer. Using genetic approaches and small molecules that destabilize the FOXM1 protein, we found that targeting this mechanism induced G2/M cell-cycle arrest and apoptosis, blocked tumor progression, and impaired metastasis. We identified a positive correlation between FOXM1 and c-Src expression in human breast cancer and show that the expression of FOXM1 target genes predicts poor outcomes and associates with the luminal B subtype, which responds poorly to currently approved therapies. These findings revealed a regulatory network centered on c-Src and FOXM1 that is a targetable vulnerability in aggressive luminal breast cancers.

Citing Articles

The Role of the Fox Gene in Breast Cancer Progression.

Pei S, Zhang D, Li Z, Liu J, Li Z, Chen J Int J Mol Sci. 2025; 26(4).

PMID: 40003882 PMC: 11855465. DOI: 10.3390/ijms26041415.


Machine learning identification of a novel vasculogenic mimicry-related signature and FOXM1's role in promoting vasculogenic mimicry in clear cell renal cell carcinoma.

Xu C, Zhang S, Lv J, Cao Y, Chen Y, Sun H Transl Oncol. 2025; 53:102312.

PMID: 39904282 PMC: 11847097. DOI: 10.1016/j.tranon.2025.102312.


FOXM1-Driven CKS1B Upregulation Promotes Pancreatic Cancer Progression and Therapeutic Resistance.

Zhang L, Wei F, Sun Q, Huang X, Zou Q, Jiang M Int J Biol Sci. 2025; 21(3):1047-1064.

PMID: 39897042 PMC: 11781179. DOI: 10.7150/ijbs.105289.


METTL14 inhibits the proliferation, migration and invasion of prostate cancer cells by increasing m6A methylation of CDK4.

Zhong X, Wang S, Yang X, Yang X, Zhou L Transl Androl Urol. 2024; 13(7):1145-1163.

PMID: 39100843 PMC: 11291409. DOI: 10.21037/tau-23-682.


Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer.

Piemonte K, Ingles N, Weber-Bonk K, Valentine M, Majmudar P, Singh S Cancer Res. 2024; 84(21):3556-3573.

PMID: 39037997 PMC: 11534525. DOI: 10.1158/0008-5472.CAN-23-2558.


References
1.
Schimmel J, Eifler K, Sigurdsson J, Cuijpers S, Hendriks I, Verlaan-de Vries M . Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein. Mol Cell. 2014; 53(6):1053-66. DOI: 10.1016/j.molcel.2014.02.001. View

2.
Brandvold K, Steffey M, Fox C, Soellner M . Development of a highly selective c-Src kinase inhibitor. ACS Chem Biol. 2012; 7(8):1393-8. PMC: 3423592. DOI: 10.1021/cb300172e. View

3.
Catterall R, Kurdieh R, McCaffrey L . Studying Cell Polarity Dynamics During Cancer Initiation Using Inducible 3D Organotypic Cultures. Methods Mol Biol. 2022; 2438:455-466. DOI: 10.1007/978-1-0716-2035-9_26. View

4.
Roche S, Fumagalli S, Courtneidge S . Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division. Science. 1995; 269(5230):1567-9. DOI: 10.1126/science.7545311. View

5.
Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E . Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014; 32(25):2794-803. DOI: 10.1200/JCO.2013.54.1870. View